Intracellular and circulating neuronal antinuclear antibodies in human epilepsy

Neurobiology of Disease

Volumn 59, Issue , 2013, Pages 206-219

  Iffland, Philip H ^a,b   Carvalho Tavares, Juliana ^a,c   Trigunaite, Abhishek ^a   Man, Shumei ^a   Rasmussen, Peter ^a   Alexopoulos, Andreas ^a   Ghosh, Chaitali ^a   Jørgensen, Trine N ^a   Janigro, Damir ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KENT STATE UNIVERSITY   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anti chromatin antibody; Anti histone antibody; Autoantibody; Autoantigen; Autoimmune; Neuroimmunology; Seizure disorders

Indexed keywords

ANTINUCLEAR ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ARTERIOVENOUS MALFORMATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMALE; FRONTAL LOBE EPILEPSY; GLIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SCHOOL CHILD; TEMPORAL LOBE EPILEPSY; WESTERN BLOTTING;

ANTI-CHROMATIN ANTIBODY; ANTI-HISTONE ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; AUTOIMMUNE; NEUROIMMUNOLOGY; SEIZURE DISORDERS;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; BLOOD-BRAIN BARRIER; BRAIN; CHILD; CHROMATIN; DNA; EPILEPSY; FEMALE; HISTONES; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROGLIA; NEURONS; SUBCELLULAR FRACTIONS; YOUNG ADULT;

EID: 84883010133     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.07.006     Document Type: Article

References (60)

1. Abe T., et al. Arterial vascular abnormality accompanying cerebral cortical dysplasia. AJNR Am. J. Neuroradiol. 1997, 18:144-146.
2. Adelow C., et al. Unprovoked seizures in multiple sclerosis and systemic lupus erythematosus: a population-based case-control study. Epilepsy Res. 2012, 101:284-287.
3. Ankeny D.P., Popovich P.G. B cells and autoantibodies: complex roles in CNS injury. Trends Immunol. 2010, 31:332-338.
4. Bechmann I., et al. What is the blood-brain barrier (not)?. Trends Immunol. 2007, 28:5-11.
5. Bharucha N.E., et al. Epidemiology in developing countries. Epilepsy: A Comprehensive Textbook 2008, 89-101. Lippincott Williams and Wilkins, Philadelphia, PA. G. Engel, T.A. Pedley (Eds.).
6. Bonnet F., et al. Lupus-like syndrome and vasculitis induced by valpromide. J. Rheumatol. 2003, 30:208-209.
7. Burlingame R.W., Boey M.L., Starkebaum G., Rubin R.L. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J. Clin. Invest. 1994, 94:184-192.
8. Chang R.S., Cole A.J. Lamotrigine-induced lupus-like syndrome: a case report and literature review. Am. J. Ther. 2012.
9. Danchenko N., et al. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006, 15:308-318.
10. David Y., et al. Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis?. J. Neurosci. 2009, 29:10588-10599.
11. David Y., et al. Astrocytic potassium and glutamate buffering controls synaptic responses in a frequency-dependent manner. Epilepsia 2009, 50:86.
12. de Vries H.E., et al. Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease. Epilepsia 2012, 53:45-52.
13. Diehl B., et al. The photic driving EEG response and photoreactive cerebral blood flow in the posterior cerebral artery in controls and in patients with epilepsy. Electroencephalogr. Clin. Neurophysiol. 1998, 107:8-12.
14. Eriksson K., et al. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res. 2001, 46:129-137.
15. Fabene P.F., et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat. Med. 2008, 14:1377-1383.
16. Galanopoulou A.S. Basic mechanisms of catastrophic epilepsy - overview from animal models. Brain Dev. 2013.
17. Galea I., et al. What is immune privilege (not)?. Trends Immunol. 2007, 28:12-18.
18. Galic M.A., et al. Postnatal inflammation increases seizure susceptibility in adult rats. J. Neurosci. 2008, 28:6904-6913.
19. Granata T., et al. Steroid treatment is effective in the treatment of status epilepticus in children. Epilepsia 2008, 1.276. Suppl. 0.
20. Granata T., et al. Immune-mediated epilepsies. Epilepsia 2011, 52:5-11.
21. Graus F., Dalmau J. CNS autoimmunity: new findings and pending issues. Lancet Neurol. 2012, 11:17-19.
22. Gu Y., Jensen P.E., Chen X. Immunodeficiency and autoimmunity in H2-O-deficient mice. J. Immunol. 2013, 190:126-137.
23. Hoftberger R., et al. Clinical neuropathology practice guide 5-2012: updated guideline for the diagnosis of anti-neuronal antibodies. Clin. Neuropathol. 2012, 31:337-341.
24. Imaoka K., Kanai Y., Yoshikawa Y., Yamanouchi K. Temporary breakdown of immunological tolerance to dsDNA and nucleohistone antigens in rabbits infected with rinderpest virus. Clin. Exp. Immunol. 1990, 82:522-526.
25. Ivens S., et al. Blood-brain barrier breakdown as a novel mechanism underlying cerebral hyperperfusion syndrome. J. Neurol. 2010, 257:615-620.
26. Janigro D. Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier. Epilepsia 2012, 53(Suppl. 1):26-34.
27. Janigro D., et al. Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells. BMC Cancer 2006, 6:72.
28. Lancaster E., Dalmau J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat. Rev. Neurol. 2012, 8:380-390.
29. Lang B., et al. New autoantibody mediated disorders of the central nervous system. Curr. Opin. Neurol. 2003, 16:351-357.
30. Levite M., Ganor Y. Autoantibodies to glutamate receptors can damage the brain in epilepsy, systemic lupus erythematosus and encephalitis. Expert Rev. Neurother. 2008, 8:1141-1160.
31. Manninger S.P., et al. An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. AJNR Am. J. Neuroradiol. 2005, 26:2290-2300.
32. Marchi N., et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med. 2004, 2:37.
33. Marchi N., et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007, 48(4):732-742.
34. Marchi N., et al. In vivo and in vitro effects of pilocarpine: relevance to epileptogenesis. Epilepsia 2007, 48(10):1934-1946.
35. Marchi N., et al. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol. Dis. 2009, 33:171-181.
36. Marchi N., et al. Transporters in drug-refractory epilepsy: clinical significance. Clin. Pharmacol. Ther. 2010, 87:13-15.
37. Marchi N., et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One 2011, 6.
38. Marchi N., et al. The blood-brain barrier hypothesis in drug resistant epilepsy. Brain 2012, 135:e211.
39. Marchi N., et al. Blood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches. Epilepsia 2012, 53:1877-1886.
40. Marchi N., et al. Modulation of peripheral cytotoxic cells and ictogenesis in a model of seizures. Epilepsia 2013, 52:1627-1634.
41. McKnight K., et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005, 65:1730-1736.
42. Michalak Z., et al. IgG leakage may contribute to neuronal dysfunction in drug-refractory epilepsies with blood-brain barrier disruption. J. Neuropathol. Exp. Neurol. 2012, 71:826-838.
43. Nabbout R. Autoimmune and inflammatory epilepsies. Epilepsia 2012, 53(Suppl. 4):58-62.
44. Nabbout R., et al. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol. 2011, 10:99-108.
45. Najm I.M., et al. Definition of the epileptogenic zone in a patient with non-lesional temporal lobe epilepsy arising from the dominant hemisphere. Epileptic Disord. 2006, 8(Suppl. 2):S27-S35.
46. Peltola J.T., et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am. J. Med. 2000, 109:712-717.
47. Prayson R.A., Frater J.L. Rasmussen encephalitis: a clinicopathologic and immunohistochemical study of seven patients. Am. J. Clin. Pathol. 2002, 117:776-782.
48. Ranua J., et al. Anticardiolipin and antinuclear antibodies in epilepsy-a population-based cross-sectional study. Epilepsy Res. 2004, 58:13-18.
49. Rigau V., et al. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 2007, 130:1942-1956.
50. Rock K.L., et al. The sterile inflammatory response. Annu. Rev. Immunol. 2010, 28:321-342.
51. Schoonen W.M., et al. Do selected drugs increase the risk of lupus? A matched case-control study. Br. J. Clin. Pharmacol. 2010, 70:588-596.
52. Seiffert E., et al. Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J. Neurosci. 2004, 24:7829-7836.
53. Siapka S., Patrinou-Georgoula M., Vlachoyiannopoulos P.G., Guialis A. Multiple specificities of autoantibodies against hnRNP A/B proteins in systemic rheumatic diseases and hnRNP L as an associated novel autoantigen. Autoimmunity 2007, 40:223-233.
54. Tu J., et al. Ultrastructure of perinidal capillaries in cerebral arteriovenous malformations. Neurosurgery 2006, 58:961-970.
55. Uva L., et al. Acute induction of epileptiform discharges by pilocarpine in the in vitro isolated guinea-pig brain requires enhancement of blood-brain barrier permeability. Neuroscience 2007, 151:303-312.
56. Van Bavel C.C., Dieker J.W., Kroeze Y., Tamboer W.P., Voll R., Muller S., Van der Vlag J. Apoptosis-induced histone H3 methylation is targeted by autoantibodies in systemic lupus erythematosus. Anns. Rheum. Dis. 2011, 70:201-207.
57. Vezzani A., et al. Therapeutic potential of new antiinflammatory drugs. Epilepsia 2011, 52:67-69.
58. Vezzani A., et al. Inflammation and epilepsy. Handb. Clin. Neurol. 2012, 107:163-175.
59. Vincent A., et al. Autoimmune channelopathies and related neurological disorders. Neuron 2006, 52:123-138.
60. Weinand M.E., et al. Cerebral blood flow and temporal lobe epileptogenicity. J. Neurosurg. 1997, 86:226-232.